Representative examples of response rates for bortezomib and bortezomib combination trials with novel agents in relapsed or relapsed and refractory myeloma highlight the difficulty in comparing across trials with varying eligibility but also point out that few combinations with novel agents appear to conclusively show major benefit when response rate alone is used as the major criterion.